{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:10:54Z","timestamp":1788149454249,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["transplantationreviews.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.trre.2016.12.001","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T20:03:13Z","timestamp":1483041793000},"page":"55-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Epstein\u2013Barr virus and renal transplantation"],"prefix":"10.1016","volume":"31","author":[{"given":"Jade","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-7455","authenticated-orcid":false,"given":"Daniel C.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2016.12.001_bb0005","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1600-6143.2006.01540.x","article-title":"Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry","volume":"6","author":"Caillard","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0010","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(84)90994-2","article-title":"Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy","volume":"1","author":"Starzl","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2016.12.001_bb0015","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/JVI.32.2.458-467.1979","article-title":"Polypeptides of the Epstein\u2013Barr virus membrane antigen complex","volume":"32","author":"Thorley-Lawson","year":"1979","journal-title":"J Virol"},{"key":"10.1016\/j.trre.2016.12.001_bb0020","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1128\/JVI.65.3.1245-1254.1991","article-title":"When Epstein\u2013Barr virus persistently infects B-cell lines, it frequently integrates","volume":"65","author":"Hurley","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.trre.2016.12.001_bb0025","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/313812a0","article-title":"Stable replication of plasmids derived from Epstein\u2013Barr virus in various mammalian cells","volume":"313","author":"Yates","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.trre.2016.12.001_bb0030","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcv.2006.03.004","article-title":"Cytomegalovirus and Epstein\u2013Barr virus subtypes\u2014the search for clinical significance","volume":"36","author":"Puchhammer-Stockl","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2016.12.001_bb0035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1086\/510854","article-title":"A study of risk factors for acquisition of Epstein\u2013Barr virus and its subtypes","volume":"195","author":"Higgins","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2016.12.001_bb0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jis646","article-title":"Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein\u2013Barr virus infection in university students","volume":"207","author":"Balfour","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2016.12.001_bb0045","doi-asserted-by":"crossref","first-page":"e64921","DOI":"10.1371\/journal.pone.0064921","article-title":"Seroprevalence of Epstein\u2013Barr virus infection in U.S. children ages 6\u201319, 2003\u20132010","volume":"8","author":"Dowd","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2016.12.001_bb0050","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/infdis\/jit321","article-title":"Age-specific prevalence of Epstein\u2013Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition","volume":"208","author":"Balfour","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2016.12.001_bb0055","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/ajt.12703","article-title":"Epstein\u2013Barr virus infection in adult renal transplant recipients","volume":"14","author":"Morton","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0060","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/ajt.12009","article-title":"Subclinical Epstein\u2013Barr virus viremia among adult renal transplant recipients: incidence and consequences","volume":"13","author":"Bamoulid","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0065","first-page":"49","article-title":"Epstein\u2013Barr virus-associated gastric carcinoma 33 years after kidney transplantation","volume":"4","author":"Lunardi","year":"2011","journal-title":"NDT Plus"},{"key":"10.1016\/j.trre.2016.12.001_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1056\/NEJM199501053320104","article-title":"The association of Epstein\u2013Barr virus with smooth-muscle tumors occurring after organ transplantation","volume":"332","author":"Lee","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2016.12.001_bb0075","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1111\/ctr.12139","article-title":"Epstein\u2013Barr virus-associated smooth muscle tumors after kidney transplantation: treatment and outcomes in a single center","volume":"27","author":"Tan","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0080","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12882-015-0096-3","article-title":"Autoimmune haemolytic anaemia associated with Epstein Barr virus infection as a severe late complication after kidney transplantation and successful treatment with rituximab: case report","volume":"16","author":"Hamilton","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.trre.2016.12.001_bb0085","first-page":"876301","article-title":"Virus-associated hemophagocytic syndrome in renal transplant recipients: report of 2 cases from a single center","volume":"2015","author":"Nanmoku","year":"2015","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.trre.2016.12.001_bb0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.12659\/AOT.883468","article-title":"Guillain-Barre syndrome in the course of EBV infection after kidney transplantation\u2014a case report","volume":"17","author":"Masajtis-Zagajewska","year":"2012","journal-title":"Ann Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0095","doi-asserted-by":"crossref","first-page":"150835","DOI":"10.1155\/2013\/150835","article-title":"Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?","volume":"2013","author":"Morscio","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.trre.2016.12.001_bb0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0105","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000144335.39913.5C","article-title":"Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?","volume":"79","author":"Ghobrial","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0110","first-page":"67","article-title":"Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment","volume":"87","author":"Muti","year":"2002","journal-title":"Haematologica"},{"issue":"Suppl. 7","key":"10.1016\/j.trre.2016.12.001_bb0115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/1469-0691.12534","article-title":"Epstein\u2013Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients","volume":"20","author":"San-Juan","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2016.12.001_bb0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/01.tp.0000188687.18972.a8","article-title":"Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System","volume":"81","author":"Smith","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0125","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1600-6143.2011.03896.x","article-title":"Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas","volume":"12","author":"Caillard","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0130","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/infdis\/152.5.876","article-title":"Epstein\u2013Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection","volume":"152","author":"Ho","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2016.12.001_bb0135","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/clinids\/20.5.1346","article-title":"Pretransplantation assessment of the risk of lymphoproliferative disorder","volume":"20","author":"Walker","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.12.001_bb0140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.TP.0000165098.49658.F3","article-title":"Lymphoproliferative disease after renal transplantation in Australia and New Zealand","volume":"80","author":"Faull","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0145","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/ajcp\/103.6.748","article-title":"Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin","volume":"103","author":"Weissmann","year":"1995","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.trre.2016.12.001_bb0150","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/01.TP.0000079832.00991.EE","article-title":"Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy","volume":"76","author":"Gulley","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0155","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00007890-200201270-00020","article-title":"Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation","volume":"73","author":"Petit","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0160","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1600-6143.2007.01736.x","article-title":"Cancer incidence among Canadian kidney transplant recipients","volume":"7","author":"Villeneuve","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0165","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1034\/j.1600-6143.2002.21019.x","article-title":"Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk","volume":"2","author":"Dharnidharka","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0170","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJM199012203232502","article-title":"Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients","volume":"323","author":"Swinnen","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2016.12.001_bb0175","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/01.tp.0000219817.18049.36","article-title":"Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients","volume":"81","author":"Opelz","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0180","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.TP.0000100826.58738.2B","article-title":"Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation","volume":"76","author":"Cherikh","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0185","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0190","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0195","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1111\/j.1600-6143.2007.01845.x","article-title":"A phase I\/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation","volume":"7","author":"Vincenti","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0200","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1600-6143.2007.01972.x","article-title":"Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab","volume":"7","author":"Kirk","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0205","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/j.1600-6143.2005.01125.x","article-title":"Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil","volume":"5","author":"Robson","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0210","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/01.tp.0000169035.10572.c6","article-title":"Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil","volume":"80","author":"Funch","year":"2005","journal-title":"Transplantation"},{"issue":"Suppl. 1","key":"10.1016\/j.trre.2016.12.001_bb0215","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/ndt\/gfm088","article-title":"Post-transplant lymphoproliferative disorder\u2014the potential of proliferation signal inhibitors","volume":"22","author":"Pascual","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0220","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1600-6143.2008.02167.x","article-title":"Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids","volume":"8","author":"McDonald","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0225","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/TP.0b013e3182200e8a","article-title":"Racial variation in the development of posttransplant lymphoproliferative disorders after renal transplantation","volume":"92","author":"Nee","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0230","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1086\/514142","article-title":"Posttransplant lymphoproliferative disease in primary Epstein\u2013Barr virus infection after liver transplantation: the role of cytomegalovirus disease","volume":"176","author":"Manez","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2016.12.001_bb0235","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.TP.0000055098.96022.F7","article-title":"Epstein\u2013Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients","volume":"75","author":"Shahinian","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0240","first-page":"173","article-title":"The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A\u2013prednisone immunosuppression","volume":"133","author":"Nalesnik","year":"1988","journal-title":"Am J Pathol"},{"key":"10.1016\/j.trre.2016.12.001_bb0245","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1432-2277.2006.00416.x","article-title":"Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation","volume":"20","author":"Bakker","year":"2007","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.12.001_bb0250","series-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.trre.2016.12.001_bb0255","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00007890-199501000-00016","article-title":"Central nervous system lymphomas in organ allograft recipients","volume":"59","author":"Penn","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0260","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/00007890-200003150-00023","article-title":"Postransplant lymphoproliferative disorder localized near the allograft in renal transplantation","volume":"69","author":"Kew","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0265","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1600-6143.2005.00776.x","article-title":"Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience","volume":"5","author":"Trofe","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0270","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1097\/00007890-199812270-00012","article-title":"Serial measurement of Epstein\u2013Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease","volume":"66","author":"Green","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0275","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/10428190400027837","article-title":"Epstein\u2013Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case\u2013control study in a renal transplant cohort","volume":"46","author":"Baiocchi","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.trre.2016.12.001_bb0280","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00007890-200207270-00009","article-title":"Persistent Epstein\u2013Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients","volume":"74","author":"Hopwood","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0285","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1399-0012.2005.00388.x","article-title":"Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder","volume":"19","author":"Tsai","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0290","first-page":"475","article-title":"The biology and clinical utility of EBV monitoring in blood","volume":"391","author":"Kanakry","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.trre.2016.12.001_bb0295","first-page":"455","article-title":"The development of prophylactic and therapeutic EBV vaccines","volume":"391","author":"Smith","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.trre.2016.12.001_bb0300","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1432-2277.2005.00145.x","article-title":"OKT3 and ganciclovir treatments are possibly related to the presence of Epstein\u2013Barr virus in serum after liver transplantation","volume":"18","author":"Barkholt","year":"2005","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.12.001_bb0305","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jmv.21953","article-title":"Soluble CD30: a serum marker for Epstein\u2013Barr virus-associated lymphoproliferative diseases","volume":"83","author":"Haque","year":"2011","journal-title":"J Med Virol"},{"key":"10.1016\/j.trre.2016.12.001_bb0310","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1600-6143.2008.02183.x","article-title":"EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial","volume":"8","author":"Tsai","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0315","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2015.08.007","article-title":"Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment","volume":"369","author":"Petrara","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.trre.2016.12.001_bb0320","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1399-0012.2012.01608.x","article-title":"Quantitative Epstein\u2013Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder","volume":"26","author":"Holman","year":"2012","journal-title":"Clin Transplant"},{"issue":"Suppl. 3","key":"10.1016\/j.trre.2016.12.001_bb0325","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ajt.12004","article-title":"Epstein\u2013Barr virus infection and posttransplant lymphoproliferative disorder","volume":"13","author":"Green","year":"2013","journal-title":"Am J Transplant"},{"issue":"Suppl. 3","key":"10.1016\/j.trre.2016.12.001_bb0330","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kidney Disease: Improving Global Outcomes Transplant Work, G","year":"2009","journal-title":"Am J Transplant"},{"issue":"Suppl. 4","key":"10.1016\/j.trre.2016.12.001_bb0335","first-page":"31","article-title":"European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment","volume":"17","author":"Transplantation, E.E.G.o.R","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0340","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1309\/AJCP9WYEXKOL9YUV","article-title":"Pattern analysis of Epstein\u2013Barr virus viremia and its significance in the evaluation of organ transplant patients suspected of having posttransplant lymphoproliferative disorders","volume":"141","author":"Cho","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.trre.2016.12.001_bb0345","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jcv.2011.11.010","article-title":"Comparison of six different specimen types for Epstein\u2013Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation","volume":"53","author":"Ruf","year":"2012","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2016.12.001_bb0350","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/00007890-200109270-00006","article-title":"Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein\u2013Barr viral load by using real-time quantitative polymerase chain reaction","volume":"72","author":"Wagner","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0355","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/blood.V92.10.3977","article-title":"Semiquantitative Epstein\u2013Barr virus polymerase chain reaction analysis of peripheral blood from organ transplant patients and risk for the development of lymphoproliferative disease","volume":"92","author":"Lucas","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.trre.2016.12.001_bb0360","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jcv.2006.06.012","article-title":"Monitoring of EBV-DNAemia by quantitative real-time PCR after adult liver transplantation","volume":"37","author":"Loginov","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2016.12.001_bb0365","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1399-3062.2004.00073.x","article-title":"Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler","volume":"6","author":"Leung","year":"2004","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2016.12.001_bb0370","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","article-title":"Treatment of solid organ transplant recipients with autologous Epstein Barr virus--specific cytotoxic T lymphocytes (CTLs)","volume":"108","author":"Savoldo","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.trre.2016.12.001_bb0375","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood.V96.13.4055","article-title":"Characterization of Epstein\u2013Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response","volume":"96","author":"Yang","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.trre.2016.12.001_bb0380","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1473-3099(07)70159-7","article-title":"Viral dynamics in transplant patients: implications for disease","volume":"7","author":"Funk","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trre.2016.12.001_bb0385","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1399-0012.2008.00938.x","article-title":"Positron emission tomography scanning in the setting of post-transplant lymphoproliferative disorders","volume":"23","author":"Blaes","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0390","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/00007890-199911270-00015","article-title":"Epstein\u2013Barr virus-induced posttransplant lymphoproliferative disorders. ASTS\/ASTP EBV-PTLD Task Force and the Mayo Clinic Organized International Consensus Development Meeting","volume":"68","author":"Paya","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0395","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2141.2010.08161.x","article-title":"Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients \u2014 BCSH and BTS guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trre.2016.12.001_bb0400","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00007890-199901270-00020","article-title":"Pediatric renal transplantation under tacrolimus-based immunosuppression","volume":"67","author":"Shapiro","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0405","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1053\/j.ajkd.2006.01.029","article-title":"Sirolimus-induced remission of posttransplantation lymphoproliferative disorder","volume":"47","author":"Cullis","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2016.12.001_bb0410","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/TP.0b013e31823ae7db","article-title":"Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients","volume":"93","author":"Sampaio","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0415","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1432-2277.2012.01485.x","article-title":"(Val-)ganciclovir prophylaxis reduces Epstein\u2013Barr virus primary infection in pediatric renal transplantation","volume":"25","author":"Hocker","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.12.001_bb0420","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1097\/00007890-199812270-00006","article-title":"Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients","volume":"66","author":"McDiarmid","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0425","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/bcmd.1998.0178","article-title":"Arginine butyrate-induced susceptibility to ganciclovir in an Epstein\u2013Barr virus (EBV)-associated lymphoma","volume":"24","author":"Mentzer","year":"1998","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.trre.2016.12.001_bb0430","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein\u2013Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.trre.2016.12.001_bb0435","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/01.tp.0000202724.07714.a2","article-title":"A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein\u2013Barr virus related posttransplant lymphoproliferative disorder","volume":"81","author":"Humar","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0440","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(07)70040-2","article-title":"Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis","volume":"8","author":"Opelz","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.trre.2016.12.001_bb0445","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1600-6143.2011.03478.x","article-title":"Monitoring infection with Epstein\u2013Barr virus among seromismatch adult renal transplant recipients","volume":"11","author":"Martin","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0450","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00277-007-0298-2","article-title":"Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution","volume":"86","author":"Choquet","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.trre.2016.12.001_bb0455","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/blood.V99.7.2592","article-title":"Infusion of autologous Epstein\u2013Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication","volume":"99","author":"Comoli","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.trre.2016.12.001_bb0460","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","article-title":"Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients \u2014 BCSH and BTS guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trre.2016.12.001_bb0465","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s11864-011-0177-x","article-title":"Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations","volume":"13","author":"Jagadeesh","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.trre.2016.12.001_bb0470","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-642-38965-8_10","article-title":"Prevention and treatment for Epstein\u2013Barr virus infection and related cancers","volume":"193","author":"Smets","year":"2014","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.trre.2016.12.001_bb0475","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2005-01-0377","article-title":"Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study","volume":"107","author":"Choquet","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.trre.2016.12.001_bb0480","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/00007890-200104270-00012","article-title":"Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients","volume":"71","author":"Tsai","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.12.001_bb0485","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder (bigstar)","volume":"11","author":"Reshef","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0490","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/ndt\/gfv260","article-title":"Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients","volume":"30","author":"Taylor","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0495","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/tri.12375","article-title":"CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality","volume":"27","author":"Rabot","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.12.001_bb0500","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/ki.2013.253","article-title":"Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival","volume":"85","author":"Serre","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2016.12.001_bb0505","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1600-6143.2005.01211.x","article-title":"Treatment of PTLD with rituximab or chemotherapy","volume":"6","author":"Elstrom","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.12.001_bb0510","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1097\/01.TP.0000079253.06061.52","article-title":"Primary brain lymphomas after kidney transplantation: presentation and outcome","volume":"76","author":"Snanoudj","year":"2003","journal-title":"Transplantation"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X16300738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X16300738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T10:38:10Z","timestamp":1601289490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X16300738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0955470X16300738"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2016.12.001","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epstein\u2013Barr virus and renal transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2016.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}